BACKGROUND: Rearrangements of the ROS1 oncogene are found in 1% to 2% of non-small cell lung cancers (NSCLC) and are regarded as mutually exclusive oncogenic driver mutations. Since the approval of targeted therapy for ROS1-positive NSCLC, ROS1 testing has become a part of the diagnostic routine. Fluorescence in situ hybridization (FISH), optionally selected for by immunohistochemistry on histological material, is a common practice for the detection of ROS1 rearrangements. However, NSCLC often is diagnosed by cytology alone, requiring predictive marker testing on cytological specimens. In the current study, the authors explored the accuracy of ROS1 immunocytochemistry (ICC) on non-cell block cytological specimens for the detection of ROS1 rearrangements. METHODS: ICC using the D4D6 antibody on an automated immunostainer was performed prospectively in the routine diagnostic setting on cytological specimens from 295 patients with NSCLC, including adenocarcinoma (241 patients), NSCLC not otherwise specified (50 patients), and other malignancies (4 patients). Any immunostaining was considered positive. RESULTS: ICC was positive in all 13 ROS1-rear- 
INTRODUCTION
Oncogenic rearrangement of the ROS1 oncogene in patients with non-small cell lung cancer (NSCLC) first was discovered in 2007 through the identification of the CD74-ROS1 oncogenic fusion protein. 1 The ROS1 gene is located on chromosome 6 (6q22) and encodes a transmembrane receptor protein from the human receptor tyrosine kinase (RTK) family. To the best of our knowledge, little is known regarding the physiological function of this receptor. ROS1 expression has been detected in nonneoplastic lung tissue, such as reactive pneumocytes and macrophages. 2 As a consequence of oncogenic fusion, ROS1 promotes tumor growth through activation of downstream oncogenic pathways. Rearrangements of the ROS1 gene occur in approximately 1% to 2% of cases of NSCLC and generally are mutually exclusive oncogenic driver mutations. [3] [4] [5] [6] In addition, several fusion partners to ROS1 have been identified and, given the frequent use of massive parallel "next-generation" sequencing (NGS) for tumor profiling, the number is likely to increase. 3, 7, 8 Regardless of the fusion partner, the tyrosine kinase domain of ROS1 is retained in all fusion events, resulting in expression of ROS1 oncogenic fusion protein with constitutive tyrosine kinase activity. 9 Recently, the tyrosine kinase inhibitor crizotinib was approved for the treatment of patients with advanced, ROS1-positive NSCLC. [10] [11] [12] Hence, ROS1 has become an important predictive marker in the personalized therapy of patients with lung cancer. Given the low prevalence of ROS1-rearranged lung cancer, it is important to rapidly and accurately identify this small subset of patients who are likely to respond to targeted therapy. ROS1 testing is recommended in patients with lung adenocarcinoma and NSCLC not otherwise specified (NOS). Because to our knowledge there are only limited data regarding ROS1 expression in squamous cell carcinoma (SCC), testing also is recommended in nonsmokers aged <50 years with SCC histology. 13 Cytology plays a key role in the diagnostic workup of patients with lung cancer. 14 In some cases, cytological specimens may even be the only source of tumor material available. Cytological specimens for the most part are comprised of bronchial brushing, bronchoalveolar lavage, and fine-needle aspiration (FNA) specimens from intrathoracic primary tumor or metastatic sites. Furthermore, in cases of advanced disease, patients commonly are diagnosed primarily with pleural metastasis by effusion cytology. In cases with sufficient tumor material (mostly effusion cytology), the specimens often are processed to formalin-fixed, paraffin-embedded (FFPE) cell blocks and the same protocols for immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) analyses can be applied as for histological specimens. However, intrathoracic FNA specimens do not always contain enough material for additional cell block preparation and predictive molecular marker testing needs to be performed on cytological specimens. In the current study, we explored the usefulness of ROS1 immunocytochemistry (ICC) on cytological specimens as a screening tool for the detection of ROS1 rearrangements in patients with NSCLC.
MATERIALS AND METHODS

Patients and Cytological Specimens
Between August 2013 and June 2016, we analyzed cytological specimens from 295 patients (156 men and 139 women with a median age of 70 years [range, 30-100 years]) with NSCLC, comprised of adenocarcinoma (241 patients), NSCLC NOS (50 patients), SCC (2 patients), and large cell neuroendocrine carcinoma (2 patients), for ROS1 status. These cases included specimens from pleural, peritoneal, and pericardial effusions (83 patients, 3 patients, and 1 patient, respectively); FNA specimens of regional lymph nodes, the lung, and distant metastases (98 patients, 56 patients, and 8 patients, respectively); 16 bronchial secretion specimens; 16 bronchial brushing specimens; 12 bronchoalveolar lavage specimens; 1 sputum specimen, and 1 smear of a fresh specimen examined by frozen section analysis.
Cytology specimens including smears and cytocentrifuge specimens (cytospins) were processed according to routine procedures using Delaunay solution (1000 mL each of acetone and absolute alcohol and 20 drops of 1 mol/L of trichloroacetic acid) or spray fix (J.T. Baker Chemical Company-Avantor, Center Valley, Pennsylvania) as a fixative and stained according to the Papanicolaou method.
The current study was exempt from institutional review board approval because it served as a means of internal test validation and quality control.
ROS1 ICC
ICC was performed in the routine diagnostic setting on Papanicolaou-stained cytological specimens in all 295 cases. After uncovering the glass slide in xylene, ICC was performed using the automated BOND-MAX immunostainer according to the manufacturer's recommendations with minor modifications (Leica Biosystems, Wetzlar, Germany). In brief, the slides were pretreated in Epitope Retrieval Solution 2 (Leica Biosystems) for 10 minutes at 808C and then incubated with the rabbit monoclonal antibody for ROS1 (dilution 1:200) for 30 minutes at room temperature (clone D4D6; Cell Signaling Technology, Danvers, Massachusetts). Antibody binding was detected using the Bond Polymer Refine Detection Kit, with 3-amino-9-ethylcarbazol (AEC) as a chromogen (Leica Biosystems).
Cytospins of the HCC-78 cell line, known to harbor a ROS1 rearrangement and to express ROS1, were used as positive controls for each reaction. Evaluation of the ICC staining was performed by a cytopathologist (T.V., S.S., or L.B.) who was blinded to the FISH results. Cytoplasmic staining in tumor cells (any percentage of positive tumor cells) of any intensity was considered positive. Benign cells within the specimens were considered to be internal negative staining controls.
ROS1 FISH
The majority of diagnostic FISH analyses of the study population (78 of 82 cases; 95%) were performed on cytological specimens fixed in Delaunay solution and stained according to the Papanicolaou method or on previously ICC-stained specimens using AEC as a chromogen. In cases with rare cancer cells or strong intermixture with benign cells, the exact locations of the cancer cells on cytological smears were recorded using relocation software (Metafer 4, version 3.3.110; MetaSystems, Baden-Wurttemberg, Germany) and an automated stage (Marzhauser Wetzlar, Wetzlar, Germany) on an epifluorescence microscope (Axioplan 2 Imaging; Carl Zeiss, Oberkochen, Germany). Before uncovering and hybridization, the cancer cells were photographed with a digital camera (AxioCam; Carl Zeiss), and the target area was permanently marked on the slide with a diamond pen. FISH then was performed using a commercially available dual-color break-apart probe with 3 0 -end (centromeric) Green Probe and 5 0 -end (telomeric)
Orange Probe (ZytoVision, Bremerhaven, Germany), as described previously. 9 FISH was performed according to the manufacturer's recommendations with minor modifications, analogous to our anaplastic lymphoma kinase (ALK) FISH protocol for cytological specimens. 15 The detailed ROS1 FISH protocol is described in the Supporting Information. FISH on FFPE biopsies (4 of 82 cases) was performed on 4-lm thick tissue sections according to the manufacturer's recommendations. The scoring of 50 cells was performed by cytotechnicians experienced in FISH analysis who were blinded to the ICC results, and all FISH results were reviewed by a cytopathologist (T.V., S.S., or L.B.). FISH results were evaluated according to the manufacturer's recommendations.
Cases were regarded as ROS1 FISH positive if a split signal (single red and single green signal with a signalseparation distance of at least 2 signal diameters) or a single green signal were present in at least 15% of the cancer cells. Inflammatory cells served as internal negative controls and demonstrated 2 fused or adjacent red/green signals, with a signal-separation distance of <2 signal diameters.
ALK Status
ALK status was determined in 287 cases, either by ICC (275 cases), IHC (clone 5A4; Novocastra, Leica Biosystems) on corresponding histological material (3 cases), or by ALK FISH (Vysis LSI ALK dual-color break-apart rearrangement probe; Abbott Molecular, Abbott Park, Illinois) on cytological (7 cases) or histological (2 cases) material. For cytological specimens, the automated BOND-MAX immunostainer was used according to the manufacturer's recommendations with minor modifications (Leica Biosystems), as previously published. 16 Seven of 8 cases in which the ALK status had not been determined were found to harbor other oncogenic driver mutations, including mutations in the epidermal growth factor receptor (EGFR) (1 case) and KRAS (6 cases) genes.
Gene Sequencing
Molecular diagnostic testing for the EGFR, KRAS, BRAF, and human epidermal growth factor receptor 2 (HER2) genes was performed by NGS methodology using the 
Statistical Analysis
The sensitivity, specificity, and positive and negative predictive values of ROS1 ICC for predicting the final ROS1 status were calculated. Only ICC cases that were confirmed by ROS1 FISH or NGS or that harbored a different mutually exclusive oncogenic driver mutation in the EGFR, KRAS, BRAF, HER2, or ALK genes were considered for the calculation. Associations between categorical variables were evaluated using the Fisher exact test (based on the binomial distribution). Differences in the mean ages of patients with ROS1-positive and ROS1-negative lung carcinomas were evaluated using the Student t test. Differences between values were considered to be statistically significant at a P value of <.05. All analyses were performed using JMP 12 software (SAS Institute Inc, Cary, North Carolina).
RESULTS
ROS1 ICC
Thirteen of 295 cases (4.4%) demonstrated ROS1 expression on ICC. Tumor cells were positive in a diffuse/homogeneous pattern, and there also often was a range in the intensity of the cytoplasmic staining (Fig. 1) . However, strong staining was observed in the majority of the tumor cells in all patient cases and cell line controls. Clinicopathological characteristics of the ROS1-positive and ROS1-negative lung carcinoma cases are summarized in Tables 1  and 2 .
To explore the stability of the ROS1 epitope during archiving, ICC was repeated retrospectively on 2 specimens aged 12 months and 1 cytological specimen aged 48 months with known ROS1 rearrangements. The reaction was found to be positive in the majority of tumor cells, albeit weaker compared with the initially performed ICC (Fig. 2) .
Correlation Between ROS1 ICC, ROS1 FISH, and Other Molecular Findings All 13 ICC-positive cases were found to have a ROS1 gene rearrangement that was confirmed by FISH (12 cases) or messenger RNA (mRNA)-based targeted NGS (1 case). It is interesting to note that FISH was false-negative in 1 ICC-positive case, in which targeted NGS revealed a ROS1 rearrangement. However, the specific ROS1 fusion partner was not identified in this analysis. In addition, we performed NGS using the Archer FusionPlex Sarcoma Rearrangement Panel (ArcherDX Inc, Boulder, Colorado) targeted gene panel, which was negative. This patient had a newly diagnosed, untreated thyroid transcription factor 1-positive adenocarcinoma. ROS1 IHC was repeated on histological material from a transbronchial biopsy of the lung and also was found to be clearly positive.
In 71 of the total of 282 ROS1 ICC-negative cases, the absence of a ROS1 rearrangement was confirmed by ROS1 FISH (69 cases) or fusion NGS (2 cases). In 137 ROS1 ICC-negative cases, we did not confirm the negative ROS1 status using ROS1 FISH or fusion NGS, but found oncogenic driver mutations in other genes generally considered to be mutually exclusive (EGFR mutations in 30 cases, KRAS mutations in 85 cases, BRAF mutations in 9 cases, and HER2 mutations in 2 cases, and ALK rearrangements in 11 cases).
In 56 ROS1 ICC-negative cases, no other oncogenic driver mutations were detected by gene sequencing or ALK ICC/FISH. In 16 ROS1 ICC-negative cases, only ALK ICC/FISH was performed and no cases of ALK rearrangement were noted. In 2 ROS1 ICC-negative cases, there was no additional molecular testing performed (Table 3) .
In 10 of 13 ROS1 ICC-positive cases, sequencing of the EGFR, KRAS, BRAF, and HER2 genes was performed and demonstrated no concurrent driver mutations. ALK status was available in 12 of 13 ROS1 ICC-positive cases, all of which demonstrated no concurrent ALK rearrangement. In 1 ROS1 ICC-positive case, there was no additional molecular testing performed.
The sensitivity, specificity, and positive and negative predictive values for ROS1 ICC compared with the ROS1 FISH/fusion NGS results were each 100%. In addition to cases with negative ROS1 FISH and fusion NGS results, cases with oncogenic driver mutations in the EGFR, KRAS, BRAF, or HER2 genes were considered to be negative controls.
One case with a ROS1 rearrangement diagnosed by FISH (37% of tumor cells with a break-apart/deletion pattern) was found to be negative by ICC. However, in this case, the corresponding positive control (HCC-78 cell line) was equally negative. We interpreted this reaction as a false-negative result due to technical reasons, and the case was omitted from the current study.
DISCUSSION
Subsets of NSCLC are defined by specific molecular alterations, thereby providing the basis for personalized cancer therapy. The majority of widely tested therapeutic targets in NSCLC involve EGFR mutations and ALK rearrangements. 17, 18 Recently, the tyrosine kinase inhibitor crizotinib also was approved for the treatment of patients with ROS1-positive advanced NSCLC, 10, 11 which necessitates systematic ROS1 testing in patients with advanced NSCLC. 19 Currently, FISH that is optionally selected for by IHC on histological material is the common diagnostic standard for the detection of ROS1 rearrangements after its use in a pivotal clinical trial. 10 An alternative approach is polymerase chain reaction (PCR)-based testing with commercially available NGS or multiplex PCR platforms using kits that cover a range of fusion genes, including ROS1. However, both FISH and PCR-based methods are expensive, time-consuming, and require a sufficient amount of tumor cells. In comparison, IHC is a more feasible and cost-effective alternative. Because of the low prevalence of ROS1 rearrangements and to limit the labor and cost of unnecessary FISH testing, ROS1 IHC has been proposed as an effective (pre)screening method with which to select ROS1 IHC-positive tumor specimens for further confirmation by FISH. 9, 13 Since the first report of ROS1 IHC on histological specimens from patients with lung cancer (published in 2012), 20 this combined testing has been implemented successfully in routine diagnostics. 13, 21 Despite the growing importance and systematic use of ROS1 IHC testing, to the best of our knowledge there still is no US Food and Drug Administration-approved or CE-IVDmarked ROS1 IHC assay available. All published data have been obtained using laboratory-developed ROS1 IHC tests established for histological material, and generally demonstrate a high sensitivity of up to 100% but greater variations in specificity. 2, 5, 22, 23 Because lung cancer often is diagnosed by cytology alone, protocols for ICC testing on cytological specimens are needed. It is likely that ROS1 IHC for histological specimens can be readily applied to FFPE cell block specimens, which have become a preferred substrate for predictive marker testing in pathology laboratories. However, cell blocks are not always available, and many laboratories still rely on classic ethanol-fixed cytological specimens for diagnosis and predictive marker analysis. To our knowledge, the current study is the first to examine the feasibility of ROS1 ICC on ethanol-fixed cytological specimens as a surrogate for ROS1 gene rearrangements. In the current series of 295 prospectively analyzed cytological specimens, ICC correctly discovered all 13 cases with a ROS1 rearrangement. In addition, the cases found to be negative for ROS1 by ICC were confirmed to be truly ROS1 negative by FISH or fusion NGS, or by the presence of other known oncogenic drivers (sensitivity of 100% and specificity of 100%).
The ICC staining characteristics for ROS1 in cytological specimens were similar to those reported in histological specimens with a diffuse cytoplasmic staining pattern. A pronounced granular or mixed cytoplasmic and membranous pattern that could pinpoint specific fusion partners was not observed in cases in the current study. 13 Although ROS1
staining of the tumor cells generally was diffuse and homogeneous, there often was a range with regard to the intensity of the cytoplasmic staining, ranging from weak to high expression within the cytological specimens and also in positive cell line controls. This nonuniform staining distribution suggests the dynamic regulation of protein expression despite the homogeneous presence of the rearrangement as evidence by FISH analysis in the current study. However, heterogeneous ROS1 expression defined by coexistent ROS1-negative and ROS1-positive areas was not evident. Some previous studies reported a limited specificity for ROS1 IHC on histological specimens, with specificity values as low as 69%. 5, 23, 24 In the current series, we found no false-positive results and observed no unspecific background staining, particularly in macrophages, thereby suggesting that the limitations regarding the specificity of ROS1 staining might be related to formalin fixation. It has been shown previously that FISH performed on cytological specimens is less problematic and often more convenient than FISH performed on histological specimens. 25, 26 To the best of our knowledge, there still are limited data regarding ROS1 FISH on cytological specimens. To our knowledge, only 1 study to date regarding ROS1 FISH analysis in cytology (cytological smears), comprising a small series of 12 cases, has been published. 27 We have established ROS1 FISH on cytological specimens in routine practice analogous to our ALK FISH protocol for cytological specimens. 15 According to the current guidelines, a minimum of 50 tumor cells are required for FISH testing, whereas the minimum number of tumor cells required for IHC is to our knowledge not clearly defined. 28 In one study, the authors proposed that only cases with at least 20 tumor cells be considered for ICC analysis. 29 However, because of homogeneous staining, we already consider a few positive tumor cells as diagnostic and sufficient to initiate confirmatory testing by FISH or NGS. The advantage of ICC over FISH is that even in specimens with rare tumor cells or strong intermixture with benign cells, positive tumor cells are readily identified because they clearly stand out due to the high contrast of the immunostain (Fig. 3) . It is interesting to note that one case in the current study was positive by ICC and negative by FISH. The subsequent analysis using targeted NGS revealed a ROS1 rearrangement. We assumed that the false-negative FISH result was due to a complex translocation that was not captured by the FISH assay. This case suggests that one should consider a third testing method in cases with positive ICC and negative FISH results so as not to miss rare variants of ROS1 rearrangements.
Discordances between IHC and FISH results already have been observed in ALK-rearranged NSCLC. [30] [31] [32] It is assumed that possible mechanisms for false-negative FISH results are complex rearrangement events caused by copy number losses in the ALK gene, a short distance between the breakpoints in the fusion genes, a large deletion between the fused genes, or DNA chromothripsis with concomitant TP53 mutation. Similar findings also have been reported for the ROS1 break-apart FISH assay. 5, 33 In 1 case with a ROS1 rearrangement confirmed by FISH, the ICC was negative in the patient sample as well as in the corresponding positive control (HCC-78 cell line). Therefore, we interpreted this reaction as falsenegative due to technical reasons. This example demonstrates the importance of using a positive control for each reaction. Several preanalytical and postanalytical factors are known to influence ICC on cytological specimens due to differences in fixation and staining methods. 34, 35 It is interesting to note that our preliminary data regarding 4 retrospectively tested specimens have suggested that the ROS1 epitope in Papanicolaou-stained slides remains stable during archiving periods of up to 4 years if they are properly sealed by a coverslip. The ICC reaction also may depend on the type of automated immunostainer used, necessitating validation on each platform individually. Rearrangement of the ROS1 gene generally is regarded as a mutually exclusive oncogenic driver alteration. In our 12 ROS1 ICC-positive cases, no concomitant mutations were found. This is in keeping with recently published data by Lin et al, 36 as well as the experience from our own clinical practice. 6 A recent study reported concomitant oncogenic driver mutations involving the EGFR, KRAS, PIK3CA, and BRAF genes in 9 of 25 ROS1-positive NSCLC cases (36%). 24 However, ROS1 status in these patients was defined by IHC, and a ROS1 rearrangement could not be demonstrated by ROS1 FISH in all ICC-positive cases. Despite the high sensitivity of ROS1 ICC for the detection of ROS1 rearrangements, rare false-negative results cannot be excluded in the current study because absolute certainty can almost never be achieved in medicine in general and biomarker testing in particular. The prevalence of ROS1 rearrangements in the current study (4.4%) is higher than that reported in the literature (1%-2%). Because the cases in the current study were analyzed prospectively, there was no selection bias. However, the current study population was enriched for adenocarcinoma.
A limitation of the current study is that no second method (FISH or fusion NGS) was performed to confirm the negative ROS1 status in 74 of the ICC-negative cases. However, it is unlikely that such an analysis would have changed the conclusion based on the 71 negative cases that were confirmed by FISH/NGS and another 137 cases confirmed as negative by the presence of another driver mutation, including pathogenic KRAS and EGFR mutations.
The data from the current study indicate that ROS1 ICC on ethanol-fixed cytological specimens is a reliable method for the detection of ROS1 rearrangements. Given its rapid evaluation, ICC can be used as a screening method in the routine diagnostic setting. Positive and equivocal ICC results should be confirmed by other molecular techniques such as FISH or NGS.
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